⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
prnewswire.com
VNDA
Tradipitant Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
globenewswire.com
VNDA
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
globenewswire.com
IONS
ALNY
NVS
BIIB
ARWR
SLN
WVE
VNDA
NSP
TCRT
AMX
CDIO
SRPT
VIR
BNTX
ARCT
GSK
PFE
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
prnewswire.com
VNDA
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
globenewswire.com
VNDA
GRFS
BHC
RDHL
MRK
TEVA
PFE
SNY
LLY
ABBV
AZN
CRCT
SPRO
CRNX
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
prnewswire.com
VNDA
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
prnewswire.com
VNDA
ANAB